The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer
- 29 April 2016
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 25 (8) , 953-959
Abstract
Purpose Studies examining adherence to endocrine therapy (ET) and breast cancer-related outcomes have traditionally used the proportion of days covered (PDC) by medication to define adherence which may mask true treatment–outcome associations for patients with different medication use behaviors. We use group-based trajectory models to examine the association between ET adherence patterns and mortality compared to a standard PDC adherence measure. Methods Using Surveillance, Epidemiology and End Results-Medicare data we included 9492 women with breast cancer who initiated ET between 2007 and 2010. We excluded women who died/recurred in the 12 months after ET initiation. We used monthly group-based trajectory models to characterize longitudinal adherence patterns and adjusted Cox proportional hazard models to estimate the association between ET adherence and mortality, comparing trajectory-based adherence to traditional PDC-based measures. Results Trajectory models identified five adherence groups: (i) high (56.2%); (ii) quick decline (9.5%); (iii) moderate decline (7.9%); (iv) quick decline, then increase (16.0%); and (v) slow decline (10.5%). Mortality was significantly associated with group assignment; compared to the high adherers, there was a significantly higher risk of death among quick declines (HR = 1.41, 95%CI = 1.09–1.72) and moderate declines (HR = 1.25, 95%CI = 1.00–1.55). Using the standard PDC adherence measure women with adherence <80% over the year had a higher risk of death than those with adherence ≥80% (HR = 1.21, 95%CI = 1.06–1.38). Conclusions Defining ET adherence using trajectory models improved adherence measurement. These models could inform clinical practice by helping to identify common adherence patterns, potential areas for intervention and better isolate adherence-related outcomes in comparative effectiveness studies. Copyright © 2016 John Wiley & Sons, Ltd.Keywords
Funding Information
- CER Strategic Initiative of UNC's Clinical and Translational Science Award (UL1TR001111)
- UNC School of Medicine
- NIH Building Interdisciplinary Research Careers in Women's Health (BIRCWH) K12 Program
- North Carolina Translational and Clinical Sciences Institute (UL1TR001111)
- Royster Society of Fellows at the University of North Carolina, Chapel Hill
This publication has 31 references indexed in Scilit:
- A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for cliniciansBreast Cancer Research and Treatment, 2013
- Group-Based Trajectory Modeling (Nearly) Two Decades LaterJournal of Quantitative Criminology, 2010
- Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancerBreast Cancer Research and Treatment, 2010
- Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancerBritish Journal of Cancer, 2008
- Early discontinuation of tamoxifenCancer, 2007
- Adherence to tamoxifen over the five-year courseBreast Cancer Research and Treatment, 2006
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Distributional Assumptions of Growth Mixture Models: Implications for Overextraction of Latent Trajectory Classes.Psychological Methods, 2003
- A SAS Procedure Based on Mixture Models for Estimating Developmental TrajectoriesSociological Methods & Research, 2001
- Multi-state models for bleeding episodes and mortality in liver cirrhosisStatistics in Medicine, 2000